Did Index Removal, ENDO 2026 Data and a $150M Raise Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative?

• In late June 2026, Mineralys Therapeutics, Inc. was removed from several Russell indices, including the Russell 3000E and Russell Microcap, while also reporting new ENDO 2026 data on lorundrostat’s effects on heart failure risk biomarkers and announcing a roughly US$150,000,000 public offering.
• Alongside revised licensing terms that give Mineralys full global rights to lorundrostat and access to up to US$500,000,000 in loan financing, the company’s recent moves suggest a stronger financial footing for advancing its lead program despite its index removals.
• We’ll now examine how Mineralys’ expanded rights to lorundrostat may influence its investment narrative and future business trajectory.

Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

Mineralys Therapeutics Investment Narrative Recap

To own Mineralys today, you have to believe lorundrostat can clear FDA review and convert a pure R&D story into a real hypertension franchise. The Russell index removals may affect trading liquidity but do not directly change the key near term catalyst, the December 22, 2026 PDUFA date, or the central risk that regulators could request more data or impose conditions that extend Mineralys’ loss making period.

The recent public offering of about US$150,000,000 is especially relevant here, because it works alongside the up to US$500,000,000 loan facility and revised lorundrostat license to give Mineralys more room to fund commercialization plans and post approval studies. While this does increase financial obligations and recent losses remain sizeable, it can also help the company stay on track toward its NDA and potential launch milestones without immediate additional equity raises.

Yet despite this added funding, investors should be aware that any setback around the December 22, 2026 PDUFA decision could...

Read the full narrative on Mineralys Therapeutics (it's free!)

Mineralys Therapeutics' narrative projects $215.7 million revenue and $23.5 million earnings by 2029. This requires earnings to improve by about $194.9 million from -$171.4 million today.

Uncover how Mineralys Therapeutics' forecasts yield a $50.88 fair value, a 84% upside to its current price.

Exploring Other Perspectives

The most optimistic analysts were projecting about US$388,000,000 of revenue and US$48,500,000 of earnings by 2029, which is far more upbeat than consensus. Their view assumes lorundrostat moves smoothly through the December 22, 2026 PDUFA decision and gains traction in a large hypertension market, while the new financing and index removal could shift how realistic those earlier expectations now look.

Explore 4 other fair value estimates on Mineralys Therapeutics - why the stock might be worth just $49.00!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Mineralys Therapeutics research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Mineralys Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mineralys Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com